Digital Quality Journey in Cell and Gene Therapy

Advanced therapies, such as cell and gene therapies, have attracted significant investment in recent years, with over 1000 clinical trials and over 900 companies currently focused on these therapies. To be successful in this rapidly growing and competitive market, companies need to adopt a long-term strategic approach to quality, considering factors such as regulatory compliance, manufacturing processes, and patient outcomes. However, there is limited agreement on ensuring consistent patient quality throughout the value chain.

Cell and gene therapies (CGTs) are a rapidly growing field in the life sciences industry, offering the potential to treat many diseases. These therapies involve using living cells or genetic material to treat or prevent disease. CGTs are complex and highly customized, presenting unique quality challenges in their manufacturing and supply chain. These include maintaining the integrity and potency of the cells or genetic material, ensuring consistency and reproducibility of the therapy, and managing the logistics of transportation and storage of these sensitive materials. To ensure safety and efficacy, rigorous Quality Control and Quality Assurance measures are essential throughout the development and manufacturing process of CGTs.

Advanced therapy manufacturing involves new and evolving technologies, which can present unique challenges in terms of quality control and assurance, including

• Lack of complete traceability to avoid patient/ product mix-ups
• Poor Cell and gene therapies quality controls across internal and external stakeholders
• Limited time and variable nature of manufacturing processes
• Incomplete manufacturing technology
• High dependency on specialized technical talent

ComplianceQuest presented a webinar on “Making the Digital Quality Journey in Cell and Gene Therapy: From Bench to Bedside to Benefit.” This talks about the challenges and opportunities in the digital quality transformation journey.

Quality in Cell and Gene Therapy is Complicated By Unique Considerations

Cell and gene therapy contain living cells or genetic material to prevent disease, which can introduce unique challenges regarding quality control. Some of these concerns mentioned below.

• Emerging Treatment:
  • A large number of ongoing trials with relatively few approvals for commercial use
  • Immature manufacturing technology
  • Evolving understanding of phase-appropriate quality and operating model for sustainable commercial manufacturing
• Patient Criticality
  • Patient safety depends on the assurance of vein-to-vein traceability
  • Available time for manufacturing is low, given the treatment criticality and the time-constrained nature of manufacturing processes
  • Highly sensitive patient data
• Complex Value Chains
  • Highly variable single-batch manufacturing
  • Supply chains are orchestrated to make a batch of one to a single patient
  • A large number of internal/external stakeholders resulted in the need for stringent quality controls across the chain
• Specialized Talent Need and Resource Shortages
  • High reliance on specialized and technical talent to ensure adherence to SOPs and quality
  • High technician turnover

Cell and gene therapy products are complex, and even small changes in the manufacturing process can significantly impact the final product. This complexity and variability make quality control especially challenging and require a combination of advanced technologies, detailed documentation, and strict adherence to best practices.

The Digital Quality Journey in Cell and Gene Therapy

Advanced therapy manufacturing often involves multiple stages of production and a wide range of suppliers and partners, which can further complicate the supply chain and increase the potential for errors or deviations. Quality leaders will need to tackle issues that are especially pertinent to cell and gene therapy and will require prioritization and investments across four key areas:

• Right-fit Process:
  • Establish a risk-based approach toward quality management processes
  • Establish a quality-minded approach early in the process, like QbD, to proactively prepare for GmP commercial manufacturing
  • Partner through industry working groups to standardize processes where necessary.
• Fundamental Technologies:
  • Prioritize technology investments based on where your organization is in the lifecycle
  • Understand how technologies will drive your patients to two key moments of truth
  • Take a wave-based approach toward implementation
• New Ways of Working:
  • Establish a culture of risk tolerance to promote rapid decision-making and autonomy
  • Leverage technologies and data for real-time collaboration and provide data needed to make decisions in ambiguous situations
• Digital Capabilities:
  • Digital end-to-end therapy development lifecycle
  • Establish a quality control tower to provide real-time transparency into quality issues, supported by proactive analytics
  • Leverage patient outcomes-related data as a feedback loop into product/process development

To address these challenges, manufacturers must have robust quality management systems to ensure that products are safe, effective, and consistent and that supply chain partners meet the necessary quality standards. Ensuring process consistency, product quality, and proper documentation is essential throughout the entire process of developing a therapy, from basic research to commercialization. This helps to ensure the safety and effectiveness of the therapy for patients and compliance with regulatory requirements. Healthcare organizations need to have robust quality management systems in place to minimize these risks and ensure that patients receive the best possible care. This includes measures such as regular monitoring and reporting of quality indicators, training and education for staff, and implementing processes for continuous improvement.

Additionally, it is important for healthcare organizations to have robust incident management and reporting systems to quickly identify and address any quality events that occur.

ComplianceQuest next-generation EQMS solution ensures quality and compliance with good manufacturing practices and other applicable regulatory standards such as ISO 9001 and US FDA by delivering the quality process. The solution has various quality management functionalities that helps businesses control and monitor quality, thus ensuring that products meet customer quality requirements.

ComplianceQuest can help your organizations with some opportunities, including:

• Improved Efficiency: Digital quality management tools can help automate many manual processes, reducing the time and resources required to complete tasks.
• Increased Visibility: Digital systems can provide real-time data and analytics, giving stakeholders a better understanding of quality performance and areas for improvement.
• Better Collaboration: Digital quality management tools can facilitate communication and collaboration among different departments and teams.
• Improved Customer Satisfaction: Digital quality management can help organizations identify and address quality issues more quickly, leading to improved customer satisfaction.
• Greater Decision Making: With real-time data and analytics, organizations can make better decisions faster.

You can also book a demo with our subject matter expert to understand more: https://www.compliancequest.com/lp/cell-and-gene-therapies-cgt/